Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Sell

C

POINT Biopharma Global Inc. Common Stock (PNT)

Pharmaceutical Preparations

https://www.pointbiopharma.com

POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.

4850 WEST 78TH STREET
INDIANAPOLIS, IN

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/01/2020

Market Cap

1,332,112,500

Shares Outstanding

106,570,000

Weighted SO

106,569,231

Total Employees

N/A

Upcoming Earnings

03/25/2024

Similar Tickers

ORIC --.--%

LYRA --.--%

INBX --.--%

EPIX --.--%

CRNX --.--%

ALXO --.--%

IMTX --.--%

BCAB --.--%

AVTE --.--%

Beta

-0.0030

Last Div

0.0000

Range

6.57-14.35

Chg

0.0200

Avg Vol

3849591

Mkt Cap

1332112500

Exch

NASDAQ

Country

US

Phone

647 812 2417

DCF Diff

-62.7249

DCF

75.2249

Div Yield

0.0000

P/S

5.4664

EV Multiple

14.0688

P/FV

3.1167

Div Yield %

0.0000

P/E

13.6930

PEG

0.0511

Payout

3.8713

Current Ratio

9.1358

Quick Ratio

9.0143

Cash Ratio

0.5588

DSO

14.0609

DIO

-0.1624

Op Cycle

13.8986

DPO

-0.3433

CCC

14.2419

Gross Margin

39.7694

Op Margin

0.4423

Pretax Margin

0.5216

Net Margin

0.3962

Eff Tax Rate

0.2404

ROA

0.2021

ROE

0.2110

ROCE

0.2455

NI/EBT

0.7596

EBT/EBIT

1.1794

EBIT/Rev

0.4423

Debt Ratio

0.0223

D/E

0.0251

LT Debt/Cap

0.0202

Total Debt/Cap

0.0245

Int Coverage

-0.0175

CF/Debt

10.5091

Equity Multi

1.1262

Rec Turnover

25.9585

Pay Turnover

-1063.1341

Inv Turnover

-2248.0770

FA Turnover

4.0924

Asset Turnover

0.5101

OCF/Share

1.0595

FCF/Share

0.8768

Cash/Share

3.2067

OCF/Sales

0.4598

FCF/OCF

0.8276

CF Coverage

10.5091

ST Coverage

58.1507

CapEx Coverage

5.8001

Div&CapEx Cov

0.2851

P/BV

3.1167

P/B

3.1167

P/S

5.4664

P/E

13.6930

P/FCF

14.3645

P/OCF

11.7983

P/CF

11.7983

PEG

0.0511

P/S

5.4664

EV Multiple

14.0688

P/FV

3.1167

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 01, 20:53 Pennant Expands Portfolio with Acquisition of Senior Living Community in Arizona GlobeNewswire Inc. Mar 07, 21:37 Pennant Group to Participate in the 2025 Oppenheimer Annual Healthcare Conference GlobeNewswire Inc. Feb 26, 01:52 SiriusPoint Announces Pricing of Secondary Offering of 4,106,631 Common Shares by Entities Associated with Daniel S. Loeb and Repurchase of 500,000 Shares by SiriusPoint Benzinga Feb 04, 03:00 Pennant Acquires Senior Living Communities in Idaho and Texas Benzinga Jan 02, 21:25 Pennant Completes Acquisition of Signature Healthcare at Home Assets GlobeNewswire Inc. Nov 12, 00:14 Pennant Group to Participate in the 2024 Stephens Annual Investment Conference GlobeNewswire Inc. Oct 03, 00:34 The Pennant Group Announces Pricing of Public Offering of Common Stock Benzinga Jan 17, 12:00 Forecasting The Future: 4 Analyst Projections For Pennant Gr GlobeNewswire Inc. Jan 02, 16:48 Pennant and John Muir Health Enter into a Home Health Joint Venture in the Bay Area, California GlobeNewswire Inc. Jan 02, 16:48 Pennant and John Muir Health Enter into a Home Health Joint Venture in the Bay Area, California Benzinga Dec 27, 12:42 Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned Benzinga Dec 27, 12:42 Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned Benzinga Dec 27, 12:42 Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned MarketWatch Dec 27, 09:47 Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target MarketWatch Dec 27, 09:47 Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target Zacks Investment Research Dec 25, 09:40 Should Value Investors Buy DaVita (DVA) Stock? Zacks Investment Research Dec 25, 09:40 Should Value Investors Buy DaVita (DVA) Stock? Benzinga Dec 19, 14:52 Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug GlobeNewswire Inc. Dec 18, 07:30 Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer GlobeNewswire Inc. Dec 14, 03:42 The Parent of a SiriusPoint Shareholder Taken Into Private Receivership

Revenue Product Segmentation